The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Linda Brady, Ph.D., NIH/NIMH (Co-Chair)
Hartmuth Kolb, Ph.D., Janssen (Co-Chair) William Potter, M.D., Ph.D., NIH/NIMH (Co-Chair Emeritus) Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics David Anderson, Ph.D., Clinical ink Anthony Bannon, Ph.D., AbbVie Daniel Barboriak, M.D., Radiological Society of North America Wade Berrettini, M.D., Ph.D., UPenn Nicole Bjorklund, Ph.D., Alzheimer’s Drug Discovery Foundation Jonathan Blackburn, Ph.D., MASSAf, Sengenics Mathias Blom, M.D., Ph.D., Rhino Health Silvana Borges, M.D., FDA Diane Bovenkamp, Ph.D., BrightFocus Foundation Danielle Boyce, The Robert Packard Center for ALS Research at Johns Hopkins Brian Campbell, Ph.D., Sage Therapeutics Maria Carrillo, Ph.D., Alzheimer’s Association Susan Catalano, Ph.D., Cognition Therapeutics Caroline Cohen, Ph.D., Sanofi Susan Croll, Ph.D., Regeneron Francesca De Simone, Ph.D., Fujirebio Ken Duckworth, M.D., NAMI Rebecca Edelmayer, Ph.D., Alzheimer’s Association Rianne Esquivel, Ph.D., Fujirebio Yuehan Feng, Ph.D., Biognosys Howard Fillit, M.D., Alzheimer’s Drug Discovery Foundation Thomas Finn, Ph.D., FDA Bernard Fischer, M.D., FDA/CDER Just Genius, M.D., UCB Danielle Graham, Ph.D., Biogen Ida Grudenberg, Ph.D., Olink Proteomics Lyn Jakeman, Ph.D., NINDS Katherine Jung, Ph.D., NIH/NIAAA Morten Karsdal, Ph.D., M.Sc., mMBA, Nordic Bioscience A/S Walter J. Koroshetz, M.D., NIH/NINDS Frank Lebeda, Ph.D., US Military Kristina Malzbender, Gates Ventures |
Eliezer Masliah, Ph.D., NIH/NIA
Bradley Miller, M.D., Ph.D., Eli Lilly David Millis, M.D., M.B.A., Ph.D., FDA/CDER Laura Mitic, Ph.D., The Bluefield Project to Cure FTD Jose Luis Molinuevo, M.D., Ph.D., Barcelona Beta Brain Research Center Mike Montalto, Ph.D., PathAI Tanya Nguyen, Ph.D., Sapient Bioanalytics Prodromos Parasoglou, Ph.D., Regeneron Lovingly Park, Ph.D., Alector Rodney Pearlman, Ph.D., The Bluefield Project to Cure FTD Mary Ann Pelleymounter, Ph.D., NIH/NINDS Chris Petropoulos, LabCorp Niels Plath, Ph.D., Lundbeck Josh Porter, Olink Proteomics Kurt Rasmussen, Ph.D., NIH/NIDA Sounder Regunathan, Ph.D., NIH/NIAAA Cristina Sampaio, M.D., Ph.D., CHDI Foundation Steve Sands, Ph.D., Amgen Bob Schafer, Ph.D., Lumos Labs Nina Schor, Ph.D., NIH/NINDS Howard Schulman, Ph.D., Allosteros Therapeutics Lamya Shihabuddin, Ph.D., Sanofi Daniel Smith, Ph.D., Alkermes Sean Smith, Ph.D., Merck Arie Struyk, M.D., Ph.D., Merck Joyce Suhy, Ph.D., BioClinica Nadine Tatton, Ph.D., The Association for Frontotemporal Degeneration Johannes Tauscher, M.D., Takeda Chris Turck, Ph.D., Max Planck Institute of Psychiatry Eugeen Vanmechelen, Ph.D., ADx Neurosciences Sean Walsh, Ph.D., Radiomics Chris Weber, Ph.D., Alzheimer’s Association Stephen Wood, Amgen Kevin Yarasheski, Ph.D., C2N Diagnositcs Henrik Zetterberg, M.D., Ph.D., University of Gothenburg |